28/03/2019 - 11:41

PharmAust’s cancer drug trial ticks safety box

28/03/2019 - 11:41

Bookmark

Save articles for future reference.

PharmAust continues to tick off the milestones at its ongoing Phase I clinical trials for its anti-cancer drug Monepantel in dogs with the escalation study showing no adverse safety issues. Beagles treated with up to 10 Monepantel tablets displayed no adverse effects or signs of toxicity after being monitored over three days. The company will now start dosing tests to determine how best to maintain long term monepantel blood levels.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options